JPRN-jRCT2080223492已完成3 期
MJR-35 phase 3 study to investigate the efficacy and safety in patients with dysmenorrhea
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 95
研究概览
简要总结
In both primary and secondary dysmenorrhea, MJR-35 at 1 mg/day relieved pain and was well tolerated.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •(1)Patients who have a painful symptom (lower abdominal pain or lumber pain) that were considered to be originated in dysmenorrhea in a degree of 3 points or more of dysmenorrhea score
- •(2)Patients diagnosed with dysmenorrhea
- •(3)Regular menstrual cycle length within 38 days
排除标准
- •(1)Patient with a complication of submucosal myoma
- •(2)Patients with a complication of lower abdominal pain or lumber pain which they can not judge whether due to dysmenorrhea or not
- •(3)Patients with a remarkable uterus swelling
- •(4)Patients with undiagnosed abnormal genital bleeding, endometrial polyp, uterine deformity or endometrial hyperplasia
- •(5)Patients with severe anemia
研究者
相似试验
已完成
3 期
MJR-35 long-term studyDysmenorrheaJPRN-jRCT2080223493MOCHIDA PHARMACEUTICAL CO., LTD.147
未知
3 期
MJR-35 Phase 3 StudyJPRN-jRCT2080222591MOCHIDA PHARMACEUTICAL CO., LTD.60
未知
2 期
MJR-35 Phase 2 StudyFunctional DysmenorrheaJPRN-jRCT2080222925MOCHIDA PHARMACEUTICAL CO., LTD.225
已完成
3 期
Efficacy and Safety Study of NPC-01 to Treat DysmenorrheaDysmenorrheaNCT01129102Nobelpharma215
已完成
2 期
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With EpilepsyEpilepsies, PartialEpilepsyNCT00210522SK Life Science, Inc.421